Literature DB >> 33032998

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.

Viktor Molander1,2, Hannah Bower3, Thomas Frisell3, Johan Askling3,2.   

Abstract

OBJECTIVE: To assess the incidence of venous thromboembolism (VTE) in rheumatoid arthritis (RA) relative to individuals without RA, and to investigate the relationship between aspects of clinical disease activity in RA and the risk of VTE.
METHODS: We conducted a nationwide register-based cohort study 2006 through 2018 using the Swedish Rheumatology Quality Register linked to other national patient registers to identify all patients with RA with at least one registered rheumatologist visit during the study period (n=46 316 patients, 322 601 visits). The Disease Activity Score 28 erythrocyte sedimentation rate (ESR) (DAS28 ESR) and its components served as the exposure, and a VTE event within the year following the visit was the main outcome. We also included general population referents (1:5) matched on age, sex and residential area.
RESULTS: Based on 2241 incident VTE events within 1 year of each included visit, and 5301 VTE events in the general population cohort, the risk ratio for VTE in RA was 1.88 (95% CI 1.65 to 2.15). Among patients with RA, the risk (and risk ratio) increased with increasing RA disease activity, from 0.52% following visits in remission to 1.08% following visits with DAS28 ESR high disease activity, RR compared with remission=2.03, 95% CI 1.73 to 2.38. Compared with the general population, also patients with RA in DAS28 ESR remission were at elevated VTE risk.
CONCLUSIONS: This study demonstrates a strong association between clinical RA disease activity measured by DAS28 ESR and the risk of VTE. RA disease activity can be used as an additional tool for VTE risk stratification in patients with RA. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; cardiovascular diseases; epidemiology; rheumatoid

Mesh:

Year:  2020        PMID: 33032998     DOI: 10.1136/annrheumdis-2020-218419

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study.

Authors:  Masaru Yoshimura; Yuichiro Fujieda; Masanari Sugawara; Michihito Kono; Masaru Kato; Isao Yokota; Olga Amengual; Yoichi M Ito; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2022-04-06       Impact factor: 3.580

Review 2.  RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?

Authors:  Vibeke Strand
Journal:  RMD Open       Date:  2021-02

Review 3.  Practical Implementation of Artificial Intelligence-Based Deep Learning and Cloud Computing on the Application of Traditional Medicine and Western Medicine in the Diagnosis and Treatment of Rheumatoid Arthritis.

Authors:  Shaohui Wang; Ya Hou; Xuanhao Li; Xianli Meng; Yi Zhang; Xiaobo Wang
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

4.  Waiting for JAK inhibitor safety data.

Authors:  Tue Wenzel Kragstrup; Bente Glintborg; Annemarie L Svensson; Christopher McMaster; Philip C Robinson; Bent Deleuran; David Fl Liew
Journal:  RMD Open       Date:  2022-02

Review 5.  Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.

Authors:  Shunsuke Mori; Fumihiko Ogata; Ryusuke Tsunoda
Journal:  Clin Rheumatol       Date:  2021-09-23       Impact factor: 2.980

6.  Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.

Authors:  Roy Fleischmann; Eduardo Mysler; Louis Bessette; Charles G Peterfy; Patrick Durez; Yoshiya Tanaka; Jerzy Swierkot; Nasser Khan; Xianwei Bu; Yihan Li; In-Ho Song
Journal:  RMD Open       Date:  2022-02

7.  Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection.

Authors:  Maria L Faquetti; Francesca Grisoni; Petra Schneider; Gisbert Schneider; Andrea M Burden
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

Review 8.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

9.  Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.

Authors:  Pauline Berthe; Lucie-Marie Scailteux; Alain Lescoat; Delphine Staumont; Guillaume Coiffier; Pierre Guéret; Alain Dupuy; Emmanuel Oger; Catherine Droitcourt
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

10.  Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?

Authors:  Gulsen Ozen; Sofia Pedro; Rebecca Schumacher; Teresa Simon; Kaleb Michaud
Journal:  RMD Open       Date:  2021-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.